Ascent Group’s AstraZeneca AZN Stock Holding History

Ascent Group’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.63M	Buy	8,256 +372	+5%	+$71.7K	0.06%	280
2025 Q4	$1.45M	Sell	7,884 -374	-5%	-$65.6K	0.05%	302
2025 Q3	$1.27M	Buy	8,258 +225	+3%	+$34.1K	0.04%	324
2025 Q2	$1.12M	Hold	8,033	–	–	0.04%	313
2025 Q1	$1.18M	Buy	+8,033	New	+$1.16M	0.05%	308
2023 Q2	–	Sell	-1,939	Closed	-$269K	–	454
2023 Q1	$269K	Sell	1,939 -117	-6%	-$15.7K	0.03%	417
2022 Q4	$279K	Buy	2,056 +91	+5%	+$11.4K	0.03%	403
2022 Q3	$231K	Sell	1,965 -1,236	-39%	-$157K	0.03%	430
2022 Q2	$424K	Sell	3,201 -174	-5%	-$22.8K	0.05%	329
2022 Q1	$448K	Buy	3,375 +523	+18%	+$62.7K	0.05%	324
2021 Q4	$337K	Buy	+2,852	New	+$336K	0.04%	360

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Ascent Group's AZN Position: Q1 2026 in Review

Ascent Group increased its AstraZeneca (AZN) stake by 4.7% in Q1 2026, buying an estimated $71.7K and bringing the position to 8,256 shares worth $1.63M. The position accounts for 0.06% of the portfolio, ranked #280.

Ascent Group first reported a position in AZN in Q4 2021 and has held it in 11 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Ascent Group held 8,256 shares of AstraZeneca worth $1.63M as of Q1 2026.
Ascent Group bought 372 AstraZeneca shares in Q1 2026, an estimated $71.7K.
AstraZeneca made up 0.06% of Ascent Group's portfolio in Q1 2026, its #280 holding.
Ascent Group first reported a position in AstraZeneca in Q4 2021 and has held it in 11 quarters since.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Ascent Group's 13F filing for Q1 2026, filed 15 May 2026.